Medpace (NASDAQ:MEDP) Announces FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 17.970-18.320 for the period, compared to the consensus earnings per share estimate of 17.680. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Medpace Price Performance

NASDAQ MEDP opened at $669.20 on Friday. Medpace has a 1-year low of $373.00 and a 1-year high of $684.52. The company has a market capitalization of $18.68 billion, a P/E ratio of 37.10, a PEG ratio of 2.97 and a beta of 1.18. The business has a 50 day moving average price of $611.66 and a 200 day moving average price of $537.67.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, topping analysts’ consensus estimates of $4.44 by $0.40. The company had revenue of $716.00 million for the quarter, compared to the consensus estimate of $714.47 million. Medpace had a return on equity of 99.76% and a net margin of 18.24%. Medpace’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.86 earnings per share. On average, research analysts expect that Medpace will post 18.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. TD Cowen boosted their price objective on shares of Medpace from $492.00 to $673.00 and gave the stock a “hold” rating in a research report on Friday. Jefferies Financial Group reiterated a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Mizuho set a $730.00 price objective on shares of Medpace in a research note on Friday. Finally, Robert W. Baird set a $699.00 price objective on shares of Medpace in a research note on Friday. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $642.91.

Insider Activity

In related news, CEO August Troendle sold 49,018 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total value of $30,788,695.98. Following the sale, the chief executive officer owned 433,372 shares of the company’s stock, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 336,140 shares of company stock worth $208,008,328. Insiders own 20.50% of the company’s stock.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: New $1 billion buyback: Medpace authorized a $1 billion repurchase program, replacing its previous authorization. The plan signals management’s confidence in cash generation and could support earnings per share by reducing the share count. Medpace Announces $1 Billion Stock Buyback Program
• Positive Sentiment: Raised 2026 outlook: The company forecast adjusted EPS of $17.97–$18.32, above the $17.68 analyst consensus, while revenue guidance of $2.8–$2.9 billion is broadly consistent with expectations. Medpace 2026 Guidance and Buyback
• Positive Sentiment: Q3 earnings beat: Medpace reported earnings of $4.84 per share versus the $4.45 consensus estimate, with revenue of approximately $716 million and year-over-year revenue growth of 8.5%. Margin expansion helped drive the earnings outperformance. Medpace Q3 Earnings Beat
• Positive Sentiment: Demand remains healthy: Net new business awards reached $873 million in the third quarter, and ending backlog increased 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace Long-Term Investor Takeaways
• Neutral Sentiment: Analyst targets moved higher but ratings remain cautious: TD Cowen raised its target to $673 from $492 and kept a “hold” rating, while Deutsche Bank increased its target to $650 and also maintained “hold.” These revisions acknowledge the improved outlook but imply limited upside at recent trading levels. TD Cowen Medpace Rating
• Negative Sentiment: Valuation remains a concern: Commentary following the results questioned whether MEDP is already pricing in much of its growth, with some analysis describing the shares as materially overvalued despite the earnings beat. This may explain the initial post-earnings hesitation.

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.